Neonatal effects of maternal nadolol therapy.
Described is the case of an infant, exposed during gestation to the beta-blocker nadolol, who experienced cardiorespiratory depression, mild hypoglycemia, and growth retardation. The longer duration of action of nadolol and the fact that it is only 30% protein bound make it less desirable than propranolol for use as a beta-blocker during pregnancy.
D005260:Female; D005316:Fetal Distress / Q000139:chemically induced; D006130:Growth Disorders / Q000139:chemically induced*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007003:Hypoglycemia / Q000139:chemically induced*; D007231:Infant, Newborn; D008297:Male; D009248:Nadolol; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects; D011412:Propanolamines / Q000009:adverse effects*
D011412:Propanolamines; D009248:Nadolol